Literature DB >> 7594652

Human papillomavirus and disease-free survival in FIGO stage Ib cervical cancer.

E R Unger1, S D Vernon, W W Thoms, R Nisenbaum, C O Spann, I R Horowitz, J P Icenogle, W C Reeves.   

Abstract

To determine if human papillomavirus (HPV) in the primary tumor was associated with disease-free survival of stage Ib cervical cancer patients, archival tissues from 47 patients were analyzed for HPV DNA by in situ hybridization (ISH) and polymerase chain reaction. HPV integration was determined by ISH signal pattern. Laboratory data were correlated with clinical parameters and disease-free survival. Kaplan-Meier estimates of 4-year disease-free survival were 56% in women with HPV detected in the primary tumor by ISH and 100% for women in whom HPV was not detected (P = .02). Four-year disease-free survival was 39% for patients with integrated HPV in the primary tumor (P = .005 vs. HPV-negative tumors and .05 vs. HPV episomal or episomal/integrated). HPV detection and integration state was not associated with any other clinical variable. Detection of integrated HPV DNA in the primary tumor was strongly associated with treatment failure.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7594652     DOI: 10.1093/infdis/172.5.1184

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  10 in total

1.  Comparison of human papillomavirus detection and typing by cycle sequencing, line blotting, and hybrid capture.

Authors:  S D Vernon; E R Unger; D Williams
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

Review 2.  Human papillomavirus, integration and cervical carcinogenesis: a clinicopathological perspective.

Authors:  K Cooper; J O McGee
Journal:  Mol Pathol       Date:  1997-02

3.  Human papillomavirus type 16 integration in cervical carcinoma in situ and in invasive cervical cancer.

Authors:  Hugo Arias-Pulido; Cheri L Peyton; Nancy E Joste; Hernan Vargas; Cosette M Wheeler
Journal:  J Clin Microbiol       Date:  2006-05       Impact factor: 5.948

4.  Detection and quantitation of human papillomavirus by using the fluorescent 5' exonuclease assay.

Authors:  A Josefsson; K Livak; U Gyllensten
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

5.  Study of viral integration of HPV-16 in young patients with LSIL.

Authors:  G Gallo; M Bibbo; L Bagella; A Zamparelli; F Sanseverino; M R Giovagnoli; A Vecchione; A Giordano
Journal:  J Clin Pathol       Date:  2003-07       Impact factor: 3.411

Review 6.  The molecular genetics of cervical carcinoma.

Authors:  P A Lazo
Journal:  Br J Cancer       Date:  1999-08       Impact factor: 7.640

7.  Human papillomavirus (HPV) DNA detection in uterine cervix cancer after radiation indicating recurrence: a systematic review and meta-analysis.

Authors:  Sasidharanpillai Sabeena; Santhosh Kuriakose; Binesh Damodaran; Nagaraja Ravishankar; Govindakarnavar Arunkumar
Journal:  J Gynecol Oncol       Date:  2019-10-22       Impact factor: 4.401

8.  The Diagnostic Value of Circulating Cell-Free HPV DNA in Plasma from Cervical Cancer Patients.

Authors:  Sara Bønløkke; Magnus Stougaard; Boe Sandahl Sorensen; Berit Bargum Booth; Estrid Høgdall; Gitte-Bettina Nyvang; Jacob Christian Lindegaard; Jan Blaakær; Jesper Bertelsen; Katrine Fuglsang; Mikael Lenz Strube; Suzan Lenz; Torben Steiniche
Journal:  Cells       Date:  2022-07-11       Impact factor: 7.666

9.  Human papillomavirus DNA and e6/e7 mRNA status in relation to survival of patients treated for cervical squamous cell carcinoma.

Authors:  Ruth Holm; Irene Kraus; Hanne Skomedal; Anita Langerød; Gunnar B Kristensen; Heidi Lyng
Journal:  Open Virol J       Date:  2008-10-24

10.  Physical status of human papillomavirus integration in cervical cancer is associated with treatment outcome of the patients treated with radiotherapy.

Authors:  Hye-Jin Shin; Jungnam Joo; Ji Hyun Yoon; Chong Woo Yoo; Joo-Young Kim
Journal:  PLoS One       Date:  2014-01-10       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.